Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
27 Março 2024 - 8:00AM
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company
developing precision genetic medicines for neuromuscular and
cardiac diseases, today announced that Bo Cumbo, President and
Chief Executive Officer, and Gabriel Brooks, M.D., Chief Medical
Officer, will present at Cantor’s Virtual Muscular Dystrophy
Symposium on Tuesday, April 2, 2024, at 8:15 am ET.
A live webcast of the presentation will be
available on the Events page of the Investors section of the
Company website or by clicking here. A webcast replay will be
archived for 30 days on the Events page.
About Solid BiosciencesSolid
Biosciences is a life sciences company focused on advancing a
portfolio of gene therapy candidates including SGT-003 for the
treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for
the treatment of catecholaminergic polymorphic ventricular
tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated
dilated cardiomyopathy, and additional assets for the treatment of
fatal cardiac diseases. Solid is advancing its diverse pipeline
across rare neuromuscular and cardiac diseases, bringing together
experts in science, technology, disease management, and care.
Patient-focused and founded by those directly impacted, Solid’s
mandate is to improve the daily lives of patients living with these
devastating diseases. For more information, please
visit www.solidbio.com.
Solid Biosciences Contact:Leah
MonteiroVP, Investor Relations &
Communications617-766-3430lmonteiro@solidbio.com
Solid Biosciences (NASDAQ:SLDB)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Solid Biosciences (NASDAQ:SLDB)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024